Abstract
We report a patient with homozygous factor H deficiency leading to permanent alternate complement activation and early onset of the hemolytic uremic syndrome. He was successfully treated with weekly infusions of fresh frozen plasma over 4 years, displaying normal blood pressure while only treated with an angiotensin converting enzyme (ACE) inhibitor, a steady level of haptoglobin, low-range proteinuria and normal creatinine clearance. By the end of the fourth year of treatment, he dramatically developed a relapse of hemolytic and uremic syndrome, displaying undetectable haptoglobin, nephrotic range proteinuria and progressive renal failure. Despite a ten-fold increase in the dosage of plasma infusion through daily plasma exchange, haptoglobin remained undetectable while circulating antigenic factor H levels reached 22–24% (normal values 65–140%). Three months following the biological onset of the relapse, a bilateral nephrectomy was performed owing to uncontrolled hypertension and rapidly progressive renal failure. The molecular mechanism of plasma resistance remained unclear while antifactor H antibodies were not detected in the plasma. We suggest that protracted administration of exogenous factor H might not be a long-term strategy in homozygous factor H deficiency.
Avoid common mistakes on your manuscript.
Introduction
Homozygous factor H deficiency leads to permanent alternate complement activation with undetectable plasma levels of C3 and factor H and is usually associated with membranoproliferative glomerulonephritis. However, a few cases of chronic hemolytic uremic syndrome (HUS) with early onset have been reported [1, 2]. Repeated infusions of fresh frozen plasma (FFP) have been demonstrated to prevent biological relapses of HUS and progression to renal failure. We report here the case of a patient who was successfully treated for 4 years but acquired a resistance to FFP.
Case report
The patient and the initial period of treatment with FFP has been reported in a previous paper [1]. Factor H deficiency was due to homozygosity of a nucleotide substitution (2770 T→A) in the factor H gene leading to a stop codon in the SCR 15 at positions 899 [2]. Viroattenuated FFP containing functional factor H antigen (91% of normal values) was infused using an implantable catheter in the right internal jugular vein from the age of 4 [1] to the age of 8 years. He received 200 ml (13.5 ml/kg once weekly) of plasma during the first year of treatment then 400 ml (22 ml/kg once weekly). Despite severe nephron loss (60% of global glomerular sclerosis), creatinine clearance remained over 100 ml/min per 1.73 m2, and plasma haptoglobin was steadily in the normal range (Fig. 1, days −336 to −53). Blood pressure was controlled with an angiotensin converting enzyme (ACE) inhibitor only, and proteinuria was below 0.5 g/l during this period. However, residual levels of plasma factor H and C3 were steadily low. No blood transfusion was needed during this period, and erythropoietin therapy was withdrawn 6 months following the onset of plasma therapy. By the end of the fourth year of treatment (Fig. 1, day 0–91), he developed massive proteinuria (4.6 g/day) with hypoalbuminemia (27 g/l) while plasma haptoglobin suddenly began being undetectable. Kidney biopsy showed no additional worsening of global glomerular sclerosis, but recent thrombi were observed in several arterioles and glomerular capillary lumens. In order to circumvent inadequate dosage of plasma, the infused volume of FFP was increased to 600 ml (20 ml/kg once weekly) then to 1,800 ml (60 ml/kg once weekly) through a plasma exchange, but it did not lead to a significant biological improvement. A series of 11 plasma exchanges of 1,800 ml were then performed for 13 days, but plasma haptoglobin could not be stabilized within the normal range despite an increased circulating level of antigenic factor H up to 24% of normal value. Bilateral nephrectomy was done by day 103 due to uncontrolled life-threatening hypertension and rapidly increasing plasma creatinine. Several attempts in searching for factor H antibodies (methods reported in [3]) were negative over this 3-month period. Long-term follow-up showed normal or increased values (960–3,540 mg/l) of plasma haptoglobin after bilateral nephrectomy when treated with hemodialysis (for 1 year following day 103) or with peritoneal dialysis while factor H and C3 remained steadily undetectable.
Discussion
Factor H deficiency due to homozygous mutations in the factor H gene is usually reported to be associated with membranoproliferative glomerulonephritis but in a few cases with early developed HUS and authentic thrombotic microangiopathy [1, 4, 5]. Those patients have undetectable plasma level of C3 and factor H. According to previous reports, low dosages of FFP were able to prevent hemolytic anemia and the progression to renal failure in homozygous patients [1, 5, 6], but the duration of reported follow-up is limited, from 8 to 18 months. Consistent with these data, our patient was successfully treated for more than 4 years with low dosages of plasma infusion once weekly, leading to a stable normal creatinine clearance, low range of proteinuria, normal blood pressure while being treated with an ACE inhibitor only, and normal plasma haptoglobin. Unexpectedly, he became dramatically resistant to plasma therapy and developed biological and histological features of a relapse of HUS despite increased volume of plasma infusion and daily delivery. Rapidly progressive renal failure was certainly due to resumed damage to his renal vasculature in addition to severe nephron loss acquired prior to plasma therapy. As a matter of fact, removal of renal endothelium with bilateral nephrectomy led to the normalization of plasma haptoglobin while complement activation remained uncontrolled with undetectable plasma factor H. Different mechanisms might explain the secondary plasma resistance of our patient. We considered the possibility of antifactor H immunization [3] but were unable to find any circulating antifactor H antibodies. Moreover, the effect of renal endothelium removal through bilateral nephrectomy [6] raises the question of a special link between factor H and kidney vasculature that could involve cooperation between factor H and adrenomedullin, a short peptide involved in antenatal development and postnatal regulation of renal vasculature [7, 8].
In conclusion, our data suggests that protracted administration of FFP might not be a successful long-term strategy to prevent HUS attacks in homozygous factor H deficiency.
References
Nathanson S, Fremeaux-Bacchi V, Deschênes G (2001) Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 16:554–556
Ohali M, Shalev H, Schlesinger M, Katz Y, Kachko L, Carmi R, Sofer S, Landau D (1998) Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 12:619–624
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V (2005) Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555–563
Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschênes G, Coppo P, Fridman WH, Weiss L (2004) Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15:787–795
Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B (2004) Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 45:415–421
Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L (2001) Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138:412–417
Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, Minamino N, Kangawa K, Ishikawa T, Fukuda M, Akimoto Y, Kawakami H, Imai T, Morita H, Yazaki Y, Nagai R, Hirata Y, Kurihara H (2001) Vasculature abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 104:1964–1971
Nishimatsu H, Hirata Y, Shindo T, Kurihara H, Kakoki M, Nagata D, Hayakawa H, Satonaka H, Sata M, Tojo A, Suzuki E, Kangawa K, Matsuo H, Kitamura T, Nagai R (2002) Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury. Studies on transgenic/Knockout mice of adrenomedullin gene. Circ Res 90:657–663
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nathanson, S., Ulinski, T., Frémeaux-Bacchi, V. et al. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 21, 1769–1771 (2006). https://doi.org/10.1007/s00467-006-0237-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-006-0237-9